Scientists test triple attack on deadly brain cancer

This study is testing whether adding an immunotherapy drug (pembrolizumab) to the standard two-part treatment for glioblastoma can help patients live longer without their cancer getting worse. It will involve about 40 adults with newly diagnosed glioblastoma who have already had surgery and initial chemo-radiation. The goal is to see if this three-part combination is safe and more effective than the current standard treatment by comparing results to past patient data.